The FDA approved the Bortezomib drug for the treatment of patients with multiple myeloma and mantle cell lymphoma. Bortezomib is a modified dipeptidyl boronic acid. The product is provided as a mannitol boronic ester which, in reconstituted form, consists of the mannitol ester in equilibrium with its hydrolysis product, the monomeric boronic acid. The drug substance exists in its cyclic anhydride form as a trimeric boroxine. The single-dose vials of Bortezomib come in 2 mg to administer intravenously and subcutaneously. Bortezomib generic medicine is readily available with numerous suppliers of generic drugs. For further information, visit https://theindianpharma.com/buy-bortenat-bortezomib-online/